Evaluation and Management of Leukocytosis with Echinocytes

Diagnostic Considerations

Echinocytes are present in 3 %–30 % of patients with pyruvate‑kinase (PK) deficiency, especially after splenectomy, making them a characteristic morphologic clue. 1
In PK deficiency the peripheral smear typically shows anisocytosis, poikilocytosis, and variable echinocyte proportions together with laboratory evidence of chronic hemolysis (elevated reticulocyte count, LDH, indirect bilirubin; low haptoglobin). 1
Diagnosis of PK deficiency requires demonstration of reduced PK enzyme activity and/or identification of pathogenic PKLR gene mutations. 1
Echinocytes may arise from delayed specimen processing or improper storage; therefore a fresh peripheral‑smear examination is essential to distinguish artifact from true pathology. 1
True pathologic echinocytes persist on fresh smears and correlate with clinical findings. 1

Do not dismiss echinocytes as artifact without confirming on a fresh specimen and correlating with the patient’s clinical picture. 1

Thrombotic microangiopathy (TMA) must be urgently excluded; it is defined by the triad of non‑immune microangiopathic hemolysis, thrombocytopenia, and organ involvement (most often renal). 3
When TMA is suspected, order ADAMTS13 activity and inhibitor titer, a complete blood count with platelet count, LDH, direct antiglobulin test, peripheral‑smear review, serum creatinine, and urinalysis without delay. 3
If ADAMTS13 activity is < 10 %, initiate therapeutic plasma exchange and methylprednisolone 1 g IV daily for 3 days immediately. 3
Physical examination for infection should specifically assess fever, tachycardia, hypotension, and identify a potential source. 5
Obtain blood cultures (and site‑specific cultures when appropriate) before starting antibiotics if infection is suspected. 5

Initial work‑up includes a complete blood count with differential, reticulocyte count, and a careful peripheral‑smear review performed by an experienced pathologist. 1
Assess hemolysis with LDH, haptoglobin, indirect bilirubin, and a direct antiglobulin test. 1
A comprehensive metabolic panel (creatinine, BUN, liver‑function tests) should be obtained to evaluate renal and hepatic status. 3
If hemolysis is confirmed without an immune cause, perform PK enzyme activity testing and consider PKLR gene‑mutation analysis. 1
When renal dysfunction is present, add urinalysis and complement studies (C3, C4, CH50) to evaluate for complement‑mediated hemolytic‑uremic syndrome. 3
If a primary bone‑marrow disorder is suspected, obtain bone‑marrow aspiration/biopsy with cytogenetics and flow cytometry; conventional cytogenetic analysis is used to detect clonal abnormalities. 6

Provide supportive care with folic‑acid supplementation. 1
Monitor for complications such as gallstones, iron overload, and aplastic crisis secondary to parvovirus infection. 1
Consider splenectomy only after excluding thrombophilic disorders, because post‑splenectomy patients have an increased risk of thromboembolic events. 4
Regularly assess iron status (serum ferritin, transferrin‑saturation) even in patients who have not received transfusions. 1

Do not delay plasma exchange while awaiting ADAMTS13 results if clinical suspicion for TTP is strong. 3
For atypical HUS (ADAMTS13 > 10 %), initiate eculizumab therapy together with meningococcal vaccination and penicillin prophylaxis. 3
Platelet transfusion is contraindicated in TTP unless there is life‑threatening bleeding. 3
Red‑cell transfusion should be reserved for symptom relief or to maintain hemoglobin at 7–8 g/dL in stable patients. 3

Start appropriate antimicrobial therapy guided by the suspected source and severity of infection. 5

Do not overlook TMA based solely on the presence of rare schistocytes; low schistocyte counts can occur early in disease evolution. 3
In PK deficiency, reticulocytosis may be disproportionately low relative to the degree of hemolysis because the spleen sequesters young red cells. 1
A normal red‑cell osmotic fragility test does not exclude PK deficiency. 1